(Q37919880)

25 August 2017

1 reference

title

Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". (English)

1 reference

25 August 2017

1 reference

3

Malcolm Brenner

1 reference

25 August 2017

Christian M Capitini

1

1 reference

25 August 2017

Stephen Gottschalk

2

1 reference

25 August 2017

Laurence J N Cooper

4

1 reference

25 August 2017

Rupert Handgretinger

5

1 reference

25 August 2017

Crystal L Mackall

6

1 reference

25 August 2017

publication date

1 September 2011

1 reference

Pediatric Hematology and Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

28

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

459-460

1 reference

A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

CD28 costimulation is essential for human T regulatory expansion and function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Safety and immunologic effects of IL-15 administration in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Regression of experimental medulloblastoma following transfer of HER2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Cytotoxicity of activated natural killer cells against pediatric solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2011.596615

10.3109/08880018.2011.596615

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference